Scientific article
Open access

Bazedoxifene as a novel strategy for treatment of pancreatic and gastric adenocarcinoma

Published inOncotarget, vol. 10, no. 34, p. 3198-3202
Publication date2019

Experimental studies have shown that the IL6/GP130/STAT3 pathway is involved in pancreatic cancer tumorigenesis and progression as well as in the development of other tumors. Bazedoxifene, a selective estrogene receptor modulator clinically available for the treatment of osteoporosis, has been shown to be an effective GP130/STAT3 signaling inhibitor through in vitro and small animal studies. Our aim was to investigate the effect of bazedoxifene on tumor progression in patients with advanced pancreatic and gastric tumors. We analyzed the data of 7 patients (5 suffering from pancreatic and 2 from gastric adenocarcinoma), with locally advanced and/or metastatic disease, median age 73 years old (range 48 - 86 years). Bazedoxifene was given orally at a dose of 20 mg per day for a median duration of 9 months (range 5 - 14 months). Two patients received bazedoxifene as monotherapy, 5 patients were under concomitant chemotherapy. Results showed tumor marker reduction in 5 patients, stable disease on CT in 5 patients and metabolic regression on PET-CT in 3 patients. Weight was gained in 4 patients. Two patients developed deep vein thrombosis and one pulmonary embolism, the treatment was otherwise well tolerated. An immunhistochemical study of pSTAT3 was performed in 6 patients, out of which 3 were positive. Our preliminary data indicate that bazedoxifene is a potential new therapeutic option for pancreatic and gastric cancer therapy, safe to use and at low cost. It might be administrated at an early stage with current strategies. Based on these preliminary results, we will initiate a prospective clinical study.

  • STAT transcription factors
  • cytokine receptor GP130
  • gastric adenocarcinoma
  • pancreatic adenocarcinoma
  • selective estrogene receptor modulator
Citation (ISO format)
BURKHARDT, Claudia et al. Bazedoxifene as a novel strategy for treatment of pancreatic and gastric adenocarcinoma. In: Oncotarget, 2019, vol. 10, n° 34, p. 3198–3202.
Main files (1)
Article (Published version)
ISSN of the journal1949-2553

Technical informations

Creation09/23/2019 4:40:00 PM
First validation09/23/2019 4:40:00 PM
Update time03/15/2023 6:15:18 PM
Status update03/15/2023 6:15:17 PM
Last indexation02/12/2024 11:44:01 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack